Prot# NU 02H8 (PCYC-0213): A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL) Combining 90-Yttrium-Zevalin® and the Redox-Modulating Agent, Motexafin Gadolinium (MGd) (Prot# 106-P115)